BioStock: Abliva’s VP of Clinical Operations on the screening achievement

Swedish biotech company Abliva has successfully met the target number of patients for screening in the first wave of the global phase II FALCON study, demonstrating their commitment to maintaining the project’s timeline. BioStock spoke with VP Clinical Operations, Dag Nesse, about this achievement in the study.  

Read the article at biostock.se:

https://www.biostock.se/en/2023/10/ablivas-vp-of-clinical-operations-on-the-screening-achievement/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/